Acast, the Largest Global Podcast Company, Launches “Acast Access” Product for Paywalled Content Distribution
Acast, the world’s largest podcast company, today announces the launch of Acast Access. The new product is the technical infrastructure for publishers to manage and distribute their exclusive paywalled content in a secure way. With Acast Access, for the first time, publishers can lock exclusive content behind their own paywall, while allowing consumers to listen to that content on their podcasting app of choice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190502005255/en/
Acast Access flow (Photo: Business Wire)
Until recently, the vast majority of podcasters have monetized their content through ad revenue. As more and more podcast publishers search for sustainable revenue streams to support their content, the industry will need to evolve support both ad revenue and subscriber revenue while creating consumption flexibility for listeners. It is in this context that Acast Access was developed - a product for publishers to distribute paywalled audio content via RSS feeds.
Ross Adams, CEO Of Acast said “At Acast, we believe the most important thing about the podcast medium is that it continues to be public and accessible and independent of any one platform. We built Acast to be independent and to bring value to podcasters by allowing their content to be shared on any device, app, or player. Acast Access takes this commitment to the next level by working with publishers to do this not just for their ad-supported podcasts but their exclusive subscription content as well.”
Johan Billgren, Acast Co-Founder and Chief Product Officer explains “Acast Access is built on the concept of having two RSS feeds for one show. One is the standard, public-RSS feed. The other is the private version of that show, the accessed-RSS. The publisher then decides what parts of the content are exclusive and only available through the accessed-RSS, and what parts are in both feeds. Acast Access then checks the anonymized user data against the publisher's API to determine which users are approved as either logged in or paying subscribers of the publisher. From the listener’s perspective, Acast Access is easy to use. It takes just two clicks to replace the public feed with the accessed version in their podcast app of choice.”
Acast first began testing paywalled content when Acast+ launched in 2016. The Acast+ paywall was only accessible through the Acast app. One publisher who used Acast+ is leading UK football podcast The Football Ramble. The Football Ramble offered one exclusive episode per month, plus an ad-free experience for all of their regular episodes, to listeners who paid a fee. For the listeners who use the Acast app, the conversion to the paywalled content was close to 50%. From listeners who didn’t pay, the feedback Acast received was directly related to the content being exclusive to the Acast app: many listeners said they would pay if they could access the paywalled episodes in their own app of choice.
This feedback led to a crucial component of Acast Access: the ability to protect content behind any third party’s paywall while letting listeners access this content in the podcast app of their choosing, such as Apple Podcasts, Overcast, Pocket Casts, and more.
Alastair Mackie, head of audio for commercial at the Financial Times, is leading the beta test of Acast Access for the Financial Times, with editorial support from Renée Kaplan, the FT's Head of Audience and New Content Strategies. Mackie said, “The Financial Times recently announced the milestone accomplishment of reaching one million paying readers and we're continuing to look for ways to attract new audiences. We've been building out our various forms of audio and are always eager to experiment as we grow beyond a traditional print and online offering. The majority of our podcast listeners are not yet subscribers and Acast Access will help us to bring tremendous value to the audio realm, incentivizing conversion for those listeners.”
Acast Access is truly a world first audio product. In addition to the ability for publishers to paywall entire episodes, they may also choose to combine private and public content in the same episode with the goal of driving conversions.
Frank Andrejasich, Associate Director for The Economist Media Lab, which is also beta testing Acast Access, said “We are always working to maximize the value of a subscription payment for our subscribers. We see Acast Access as helping us to take a more innovative approach to audio subscription and helping to grow the opportunities for our podcasts, including the recently launched Intelligence daily podcast. We want to give our listeners as many reasons as possible to stay connected to The Economist.”
Frank Andrejasich, Product Manager for New Product Development at The Economist, which is also beta testing Acast Access, said “We are always trying to help subscribers unlock value from their subscription to The Economist, and audio has been a key differentiator for us for many years. Acast Access offers us the opportunity to take a more innovative approach to subscription audio content and will allow our subscribers to listen to subscriber-only audio in the same places they listen to our award-winning Economist Radio podcasts.”
About Acast
Acast is the world’s largest podcast company. Since 2014, Acast has been the engine powering audio for makers all over the world. At its core, Acast connects audio makers with the financial support they need to create amazing content while also delivering the audience they want. Acast works with podcasts globally including My Dad Wrote a Porno, Off Menu, David Tennant Does A Podcast With, The Adam Buxton Podcast, Sanspants Radio, Alice & Bianca, Watch What Crappens and Varvet as well as those of publishers such as the Times, the Economist, Guardian, VICE and Vogue. As a global business, Acast has offices around the world from Stockholm to Sydney and a team of 100 talented audio lovers working diligently to create a sustainable audio and voice ecosystem to ensure that the audio industry continues to grow and flourish. Acast was founded by Karl Rosander and Mans Ulvestam together with co-founder Johan Billgren.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005255/en/
Contact information
Kara Silverman
kara@acast.com
201-499-7889
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom